Skip to main content

Table 9 Anti-Tat cellular response according to anti-Tat Abs and HIV-1 DNA vs anti-Tat immune responses

From: HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial

 

n/N (b)

Percentage

 

Anti-Tat cellular response in vaccinees (a)

   

IgM+ and IgG+

60/67

89.5

 

IgM+, IgG+ or IgA+

34/40

85.0

 

Ab Negative

22/29

75.9

 

HIV-1 DNA (log 10 copies/10 6 CD4 + T cells)

Year (c)

Mean ± s.e. (d)

n

Vaccinees

   

Anti-Tat Ab negative and cellular positive

   
 

2nd

−0.08 ± 0.09

21

 

3rd

−0.21 ± 0.11

11

 

2nd and 3rd

−0.08 ± 0.08

22

Anti-Tat Ab negative and cellular negative

   
 

2nd

0.09 ± 0.14

7

 

3rd

0.10 ± 0.57

3

 

2nd and 3rd

0.06 ± 0.17

7

OBS subjects(e)

   

Anti-Tat Ab negative and cellular positive

 

2nd

−0.12 ± 0.07

37

 

3rd

−0.16 ± 0.07(*)

28

 

2nd and 3rd

−0.13 ± 0.07

37

Anti-Tat Ab negative and cellular negative

   
 

2nd

−0.07 ± 0.07

8

 

3rd

0.09 ± 0.12

8

 

2nd and 3rd

0.00 ± 0.05

8

  1. (a)Cumulative anti-Tat cellular responses up to 48 weeks in vaccinees. Anti-Tat cellular responses included IFN-γ, IL-4, and IL-2 production and CD4+ or CD8+ T cell proliferative responses.
  2. (b)n = number of subjects positive for anti-Tat cellular responses; N = total number of evaluated subjects. (c)Year since first immunization: 48, 72, 84, 96 weeks (2nd year); 108, 120, 132, 144 weeks (3rd year). (d)s.e. = standard error; (*) p = 0.0426, Student’s t-test for paired data. (e)The frequency of anti-Tat cellular responses in OBS subjects was 45/61 (74%).